Medexus Pharmaceuticals Inc. was established in September 2018 through the amalgamation of three established pharmaceutical companies:

• Pediapharm Inc. was a Canadian specialty pharmaceutical company focused in meeting the healthcare needs of the pediatric community with prescription and over-the-counter (OTC) medications. Established in 2008, Pediapharm had engaged in numerous commercial agreements with partners in Canada and other countries. Their innovative product portfolio included NYDA, Relaxa, and Rupall.
• Medexus Inc. was a well-established specialty pharmaceutical company that focused on acquiring and commercializing innovative prescription and over-the-counter (OTC) pharmaceutical products. Established in 2000, The company had expertise in areas such as rheumatology, neurology, and auto-immune diseases. Notable products included Metoject and Oralvisc.
• Medac Pharma, a privately held company based in the United States established in 2012, was a subsidiary of medac GmbH, a well-known global pharmaceutical company specializing in rheumatology, hematology and oncology, providing advanced therapeutics for the treatment of cancer and autoimmune diseases. Key products were Rasuvo and treosulfan.

This merger created a stronger commercial platform and bolstered the newly formed company, Medexus Pharmaceuticals Inc., position in the pharmaceutical industry to better address unmet medical needs and improve patients’ outcomes through its innovative specialty products.